Details for Patent: 10,376,505

Which drugs does patent 10,376,505 protect, and when does it expire?

Patent 10,376,505 protects RELISTOR and is included in one NDA.

This patent has fifty-six patent family members in thirty-two countries.

Summary for Patent: 10,376,505

Title:	Oral formulations and lipophilic salts of methylnaltrexone
Abstract:	The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
Inventor(s):	Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
Assignee:	Wyeth LLC
Application Number:	US16/219,159
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,376,505
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Device; Dosage form;

error: insufficient information

Drugs Protected by US Patent 10,376,505

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Salix	RELISTOR	methylnaltrexone bromide	TABLET;ORAL	208271-001	Jul 19, 2016		RX	Yes	Yes	10,376,505		Y

International Family Members for US Patent 10,376,505

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	080491
Australia	2011224275
Brazil	112012022873
Canada	2789798
Chile	2012002192